INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

460

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Temozolomide
DRUG: Neratinib
DRUG: QBS10072S
DRUG: Abemaciclib
DRUG: CC-115

Sponsor

Patrick Wen, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]